Focal Ablation with Focal Cryotherapy or High Intensity Frequency Ultrasound for the Treatment of Men with Localized Prostate Cancer
This clinical trial evaluates the effectiveness and safety of focal therapy (focal cryotherapy or high intensity frequency ultrasound) for the treatment of men with localized prostate cancer. Focal cryotherapy kills tumor cells by freezing them. High intensity frequency ultrasound uses highly focused ultrasound waves to produce heat and destroy tumor cells. The FDA has approved this technology for performing focal therapy for prostate cancer, however the American Urological Society guidelines recommend treatment via a clinical trial or prospective registry to track long term outcomes. Focal therapy is not currently standard of care, however it is being used in many medical centers, and the results need to be carefully monitored over time. The best management of intermediate risk prostate cancers is not known. Current standard of care is active surveillance or whole prostate gland therapy such as radical prostatectomy or radiation. Risks associated with whole gland therapy include reduced quality of life related to urinary, sexual, bowel, and hormonal function. The decision of which focal therapy will be determined based on the patient and clinical factors decided by the doctor and will be scheduled at least 6 months from enrollment in the study.